Orders
This page...
Forms
Order Kits
Order Kits
Order Kits
Loading...
×
Cone-Rod Dystrophy Sequencing Panel
- Summary and Pricing
- Clinical Features and Genetics
- Citations
- Methods
- Ordering/Specimens
Order Kits
TEST METHODS
- NextGen Sequencing using PG-Select Capture Probes
- Deletion/Duplication Testing via Array Comparative Genomic Hybridization
NextGen Sequencing
| Test Code | Test Copy Genes | CPT Code Copy CPT Codes | |
|---|---|---|---|
| 1337 | ABCA4 | 81408 | Add |
| ADAM9 | 81479 | ||
| AIPL1 | 81479 | ||
| BEST1 | 81406 | ||
| C8orf37 | 81479 | ||
| CABP4 | 81479 | ||
| CACNA1F | 81479 | ||
| CACNA2D4 | 81479 | ||
| CDHR1 | 81479 | ||
| CERKL | 81479 | ||
| CFAP410 | 81479 | ||
| CNGB3 | 81479 | ||
| CNNM4 | 81479 | ||
| CRX | 81404 | ||
| DRAM2 | 81479 | ||
| GUCA1A | 81479 | ||
| GUCY2D | 81479 | ||
| KCNV2 | 81479 | ||
| PDE6C | 81479 | ||
| PDE6H | 81479 | ||
| PITPNM3 | 81479 | ||
| POC1B | 81479 | ||
| PROM1 | 81479 | ||
| PRPH2 | 81404 | ||
| RAB28 | 81479 | ||
| RAX2 | 81479 | ||
| RDH5 | 81479 | ||
| RGS9 | 81479 | ||
| RGS9BP | 81479 | ||
| RIMS1 | 81479 | ||
| RPGR | 81479 | ||
| RPGRIP1 | 81479 | ||
| SEMA4A | 81479 | ||
| TTLL5 | 81479 | ||
| UNC119 | 81479 | ||
| Full Panel Price* | $640.00 | ||
| Test Code | Test Copy Genes | Total Price | CPT Codes Copy CPT Codes | |
|---|---|---|---|---|
| 1337 | Genes x (35) |
$640.00 | 81404(x2), 81406, 81408, 81479(x31) | Add |
Pricing Comments
We are happy to accommodate requests for single genes or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered on our PGxome Custom Panel.
Targeted Testing
For ordering sequencing of targeted known variants, please proceed to our Targeted Variants landing page.
Turnaround Time
The great majority of tests are completed within 20 days.
Clinical Sensitivity
A mutation spectrum analysis by Sanger sequencing of eight autosomal dominant (ad) Cone-Rod Dystrophy (adCRD) associated genes identified pathogenic variations in ~50% of all adCD (cone dystrophy) and adCRD cases (Kohl et al. 2012. PubMed ID: 22183351). Causative variants were identified in GUCY2D (23%), PRPH2 (11%), GUCA1A (8%), CRX (4%), and PROM1 (2%). No pathogenic variants were detected in AIPL1, UNC119 and PITPNM3, suggesting they may have a minor role in adCD and adCRD . A study based on literature searches (RetNet) reports that the autosomal recessive Cone-Rod Dystrophy (arCRD) genes ABCA4, RPGRIP1, ADAM9 and CERKL are responsible for nearly 40% of arCRD cases, ABCA4 being the major causative gene (den Hollander et al. 2010. PubMed ID: 20811160). Whole exome sequencing in 47 Chinese Families with CRD identified 14 potential pathogenic variations in 10 families (21.3%). These causative sequence variations were found in 6 of the 25 CRD-associated genes: CNGB3 (6.4%), PDE6C (4.3%), RPGR (4.3%), ABCA4 (2.0%), RPGRIP1 (2.0%), and CACNA1F (2.0%). The authors report that this is the first systemic exome-sequencing analysis of all 25 CRD-associated genes (Huang et al. 2013. PubMed ID: 23776498). All these genes together account for only about half of the ad/ar CRD cases, which indicates that there are still many genes that need to be identified (Hamel. 2007. PubMed ID: 17270046).
Del/Dup via aCGH
| Test Code | Test Copy Genes | Price | CPT Code Copy CPT Codes | |
|---|---|---|---|---|
| 600 | ABCA4 | $990.00 | 81479 | Add |
| ADAM9 | $990.00 | 81479 | ||
| AIPL1 | $990.00 | 81479 | ||
| BEST1 | $990.00 | 81479 | ||
| C8orf37 | $990.00 | 81479 | ||
| CABP4 | $990.00 | 81479 | ||
| CACNA1F | $990.00 | 81479 | ||
| CACNA2D4 | $990.00 | 81479 | ||
| CDHR1 | $990.00 | 81479 | ||
| CERKL | $990.00 | 81479 | ||
| CFAP410 | $990.00 | 81479 | ||
| CNGB3 | $990.00 | 81479 | ||
| CNNM4 | $990.00 | 81479 | ||
| CRX | $990.00 | 81479 | ||
| GUCA1A | $990.00 | 81479 | ||
| GUCY2D | $990.00 | 81479 | ||
| KCNV2 | $990.00 | 81479 | ||
| PDE6C | $990.00 | 81479 | ||
| PITPNM3 | $990.00 | 81479 | ||
| PROM1 | $990.00 | 81479 | ||
| PRPH2 | $990.00 | 81479 | ||
| RAX2 | $990.00 | 81479 | ||
| RDH5 | $990.00 | 81479 | ||
| RIMS1 | $990.00 | 81479 | ||
| RPGR | $990.00 | 81479 | ||
| RPGRIP1 | $990.00 | 81479 | ||
| SEMA4A | $990.00 | 81479 | ||
| UNC119 | $990.00 | 81479 | ||
| Full Panel Price* | $1490.00 | |||
| Test Code | Test Copy Genes | Total Price | CPT Codes Copy CPT Codes | |
|---|---|---|---|---|
| 600 | Genes x (28) |
$1490.00 | 81479(x28) | Add |
Pricing Comments
|
# of Genes Ordered |
Total Price |
|
1 |
$990 |
|
2-5 |
$1190 |
|
6-10 |
$1290 |
|
11-100 |
$1490 |
|
Over 100 |
Call for quote |
Turnaround Time
The great majority of tests are completed within 20 days.
Clinical Sensitivity
Gross deletions/duplications have been reported in BEST1, PRPH2, CRX, CNGB3, ABCA4, GUCY2D, CACNA2D4, CNNM4, KCNV2, RGS9BP, RPGR, and CACNA1F (Human Gene Mutation Database).
Clinical Features
Cone-rod dystrophy (CORD/CRD) is a rare hereditary retinal disorder with a worldwide prevalence of ~1 in 40,000. CRD is characterized by dysfunction or degeneration of cone photoreceptors with relative preservation of rod function in the initial stages. The most common symptoms are photophobia and epiphora in bright light, decreased visual acuity, and dyschromatopsia. Fundus changes may vary from mild pigment granularity to a distinct atrophic lesion in the central macula. As the disease progresses, degeneration of rod photoreceptors also occurs and leads to progressive night blindness and peripheral visual field loss (Hamel. 2007. PubMed ID: 17270046).
Genetics
Non syndromic CRD is genetically heterogeneous and exhibits autosomal dominant (AD), autosomal recessive (AR) and, rarely, X-linked (XL) inheritance (Hamel. 2007. PubMed ID: 17270046). To date, over 25 genes have been implicated in different forms of CRD (RetNet). Causative variants in the genes ABCA4, ADAM9, AIPL1, C21orf2, C8orf37, CABP4, CACNA2D4, CDHR1, CERKL, CNGB3, CNNM4, DRAM2, KCNV2, PDE6C, POC1B, RAB28, RPGRIP1, RGS9, RGS9BP and TTLL5 are inherited in an AR manner. Causative variants in the genes CRX, GUCA1A, GUCY2D, PITPNM3, RAX2, RIMS1, SEMA4A, UNC119 show AD inheritance. Pathogenic variants in BEST1, PDE6H, PROM1 and PRPH2 are inherited in both autosomal dominant and recessive manner. CACNA1F and RPGR are the only genes associated with XL-CRD in male patients. Females are often but not always asymptomatic, possibly due to random X inactivation. RPGR is a major gene responsible for ~70% of the XL- Retinitis pigmentosa (RP) cases. Currently, its contribution to the XL-CRD is unknown (Hamel. 2007. PubMed ID: 17270046). RPGR gene open reading frame 15 (ORF15) sequence analysis is not included in this panel. Due to the genetic heterogeneity, screening of all the CRD-associated genes is recommended. Most of the CRD-associated genes are also involved in other types of retinal dystrophies such as RP, macular dystrophies and cone dystrophies. Many of these genes encode proteins that have major roles in disc morphogenesis and the membrane- trafficking of photoreceptors (Sung and Chuang. 2010. PubMed ID: 20855501).
See individual gene test descriptions for further information on molecular biology of gene products and mutation spectra.
Testing Strategy
For this Next Generation Sequencing (NGS) test, sequencing is accomplished by capturing specific regions with an optimized solution-based hybridization kit, followed by massively parallel sequencing of the captured DNA fragments.
For Sanger sequencing, polymerase chain reaction (PCR) is used to amplify targeted regions. After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit. PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer. In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.
This panel typically provides >98% coverage of all coding exons of the genes listed, plus ~10 bases of flanking noncoding DNA. We define coverage as ≥20X NGS reads or Sanger sequencing. Exon 1 of CERKL, exon 15 in RPGR, exon 1 of RPGRIP1, and a region in RIMS1 exon 1 are not covered for technical reasons.
If one single suspected pathogenic variant is found in ABCA4, CERKL, or RPGRIP1, we will complete coverage of these genes using sanger sequencing, which includes documented deep intronic variants in ABCA4.
Indications for Test
All patients with symptoms suggestive of Cone-rod dystrophy are candidates.
Genes
| Inheritance | Abbreviation |
|---|---|
| Autosomal Dominant | AD |
| Autosomal Recessive | AR |
| X-Linked | XL |
| Mitochondrial | MT |
Diseases
Related Tests
CONTACTS
Genetic Counselors
- Genetic Counselor Team - clinicaldnatesting@preventiongenetics.com
Geneticist
- Madhulatha Pantrangi, PhD - madhu.pantrangi@preventiongenetics.com
Citations
Order Kits
TEST METHODS
- NextGen Sequencing using PG-Select Capture Probes
- Deletion/Duplication Testing via Array Comparative Genomic Hybridization
NextGen Sequencing using PG-Select Capture Probes
Test Procedure
We use a combination of Next Generation Sequencing (NGS) and Sanger sequencing technologies to cover the full coding regions of the listed genes plus ~10 bases of non-coding DNA flanking each exon. As required, genomic DNA is extracted from the patient specimen. For NGS, patient DNA corresponding to these regions is captured using an optimized set of DNA hybridization probes. Captured DNA is sequenced using Illumina’s Reversible Dye Terminator (RDT) platform (Illumina, San Diego, CA, USA). Regions with insufficient coverage by NGS are often covered by Sanger sequencing.
For Sanger sequencing, Polymerase Chain Reaction (PCR) is used to amplify targeted regions. After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit. PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer. In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.
Patient DNA sequence is aligned to the genomic reference sequence for the indicated gene region(s). All differences from the reference sequences (sequence variants) are assigned to one of five interpretation categories, listed below, per ACMG Guidelines (Richards et al. 2015).
(1) Pathogenic Variants
(2) Likely Pathogenic Variants
(3) Variants of Uncertain Significance
(4) Likely Benign Variants
(5) Benign Variants
Human Genome Variation Society (HGVS) recommendations are used to describe sequence variants (http://www.hgvs.org). Rare variants and undocumented variants are nearly always classified as likely benign if there is no indication that they alter protein sequence or disrupt splicing.
Analytical Validity
As of March 2016, 6.36 Mb of sequence (83 genes, 1557 exons) generated in our lab was compared between Sanger and NextGen methodologies. We detected no differences between the two methods. The comparison involved 6400 total sequence variants (differences from the reference sequences). Of these, 6144 were nucleotide substitutions and 256 were insertions or deletions. About 65% of the variants were heterozygous and 35% homozygous. The insertions and deletions ranged in length from 1 to over 100 nucleotides.
In silico validation of insertions and deletions in 20 replicates of 5 genes was also performed. The validation included insertions and deletions of lengths between 1 and 100 nucleotides. Insertions tested in silico: 2200 between 1 and 5 nucleotides, 625 between 6 and 10 nucleotides, 29 between 11 and 20 nucleotides, 25 between 21 and 49 nucleotides, and 23 at or greater than 50 nucleotides, with the largest at 98 nucleotides. All insertions were detected. Deletions tested in silico: 1813 between 1 and 5 nucleotides, 97 between 6 and 10 nucleotides, 32 between 11 and 20 nucleotides, 20 between 21 and 49 nucleotides, and 39 at or greater than 50 nucleotides, with the largest at 96 nucleotides. All deletions less than 50 nucleotides in length were detected, 13 greater than 50 nucleotides in length were missed. Our standard NextGen sequence variant calling algorithms are generally not capable of detecting insertions (duplications) or heterozygous deletions greater than 100 nucleotides. Large homozygous deletions appear to be detectable.
Analytical Limitations
Interpretation of the test results is limited by the information that is currently available. Better interpretation should be possible in the future as more data and knowledge about human genetics and this specific disorder are accumulated.
When Sanger sequencing does not reveal any difference from the reference sequence, or when a sequence variant is homozygous, we cannot be certain that we were able to detect both patient alleles. Occasionally, a patient may carry an allele which does not amplify, due to a large deletion or insertion. In these cases, the report will contain no information about the second allele. Our Sanger and NGS Sequencing tests are generally not capable of detecting Copy Number Variants (CNVs).
We sequence all coding exons for each given transcript, plus ~10 bp of flanking non-coding DNA for each exon. Test reports contain no information about other portions of the gene, such as regulatory domains, deep intronic regions or any currently uncharacterized alternative exons.
In most cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.
Our ability to detect minor sequence variants due to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.
Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR.
Unless otherwise indicated, DNA sequence data is obtained from a specific cell-type (usually leukocytes from whole blood). Test reports contain no information about the DNA sequence in other cell-types.
We cannot be certain that the reference sequences are correct.
Rare, low probability interpretations of sequencing results, such as for example the occurrence of de novo mutations in recessive disorders, are generally not included in the reports.
We have confidence in our ability to track a specimen once it has been received by PreventionGenetics. However, we take no responsibility for any specimen labeling errors that occur before the sample arrives at PreventionGenetics.
Deletion/Duplication Testing via Array Comparative Genomic Hybridization
Test Procedure
Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are extracted and analyzed.
Analytical Validity
PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene. PreventionGenetics has established and verified this test's accuracy and precision.
Analytical Limitations
Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.
This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.
aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.
Breakpoints, if occurring outside the targeted gene, may be hard to define.
The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.
Order Kits
Ordering Options
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
REQUISITION FORM
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
SPECIMEN TYPES
WHOLE BLOOD
(Delivery accepted Monday - Saturday)
- Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
- For small babies, we require a minimum of 1 ml of blood.
- Only one blood tube is required for multiple tests.
- Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
- During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
- In cold weather, include an unfrozen ice pack in the shipping container as insulation.
- At room temperature, blood specimen is stable for up to 48 hours.
- If refrigerated, blood specimen is stable for up to one week.
- Label the tube with the patient name, date of birth and/or ID number.
DNA
(Delivery accepted Monday - Saturday)
- Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
- For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
- DNA may be shipped at room temperature.
- Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
- We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.
CELL CULTURE
(Delivery preferred Monday - Thursday)
- PreventionGenetics should be notified in advance of arrival of a cell culture.
- Culture and send at least two T25 flasks of confluent cells.
- Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
- Send specimens in insulated, shatterproof container overnight.
- Cell cultures may be shipped at room temperature or refrigerated.
- Label the flasks with the patient name, date of birth, and/or ID number.
- We strongly recommend maintaining a local back-up culture. We do not culture cells.
Loading...
×
Copy Text to Clipboard
×